Edgewood Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $572K | Hold |
10,000
| – | – | 0.01% | 73 |
|
|
2026
Q1 | $565K | Buy |
+10,000
| New | +$583K | ﹤0.01% | 72 |
|
|
2025
Q4 | – | Sell |
-15,000
| Closed | -$812K | – | 90 |
|
|
2025
Q3 | $812K | Hold |
15,000
| – | – | ﹤0.01% | 66 |
|
|
2025
Q2 | $825K | Hold |
15,000
| – | – | ﹤0.01% | 63 |
|
|
2025
Q1 | $1.06M | Hold |
15,000
| – | – | ﹤0.01% | 65 |
|
|
2024
Q4 | $986K | Hold |
15,000
| – | – | ﹤0.01% | 65 |
|
|
2024
Q3 | $1.05M | Hold |
15,000
| – | – | ﹤0.01% | 61 |
|
|
2024
Q2 | $1.23M | Hold |
15,000
| – | – | ﹤0.01% | 61 |
|
|
2024
Q1 | $1.31M | Hold |
15,000
| – | – | ﹤0.01% | 56 |
|
|
2023
Q4 | $1.45M | Hold |
15,000
| – | – | ﹤0.01% | 51 |
|
|
2023
Q3 | $1.33M | Hold |
15,000
| – | – | ﹤0.01% | 51 |
|
|
2023
Q2 | $1.3M | Hold |
15,000
| – | – | ﹤0.01% | 53 |
|
|
2023
Q1 | $1.46M | Hold |
15,000
| – | – | ﹤0.01% | 48 |
|
|
2022
Q4 | $1.55M | Hold |
15,000
| – | – | 0.01% | 45 |
|
|
2022
Q3 | $1.27M | Hold |
15,000
| – | – | ﹤0.01% | 43 |
|
|
2022
Q2 | $1.24M | Hold |
15,000
| – | – | ﹤0.01% | 46 |
|
|
2022
Q1 | $1.16M | Hold |
15,000
| – | – | ﹤0.01% | 51 |
|
|
2021
Q4 | $1.32M | Hold |
15,000
| – | – | ﹤0.01% | 50 |
|
|
2021
Q3 | $1.16M | Hold |
15,000
| – | – | ﹤0.01% | 51 |
|
|
2021
Q2 | $1.25M | Hold |
15,000
| – | – | ﹤0.01% | 52 |
|
|
2021
Q1 | $1.13M | Hold |
15,000
| – | – | ﹤0.01% | 52 |
|
|
2020
Q4 | $1.31M | Buy |
15,000
+5,000
| +50% | +$396K | ﹤0.01% | 46 |
|
|
2020
Q3 | $761K | Buy |
10,000
+5,000
| +100% | +$506K | ﹤0.01% | 51 |
|
|
2020
Q2 | $617K | Hold |
5,000
| – | – | ﹤0.01% | 55 |
|
|
2020
Q1 | $422K | Hold |
5,000
| – | – | ﹤0.01% | 60 |
|
|
2019
Q4 | $423K | Buy |
+5,000
| New | +$378K | ﹤0.01% | 65 |
|
|
2016
Q4 | – | Sell |
-11,030
| Closed | -$1.02M | – | 89 |
|
|
2016
Q3 | $1.02M | Buy |
11,030
+6,030
| +121% | +$568K | 0.01% | 48 |
|
|
2016
Q2 | $389K | Hold |
5,000
| – | – | ﹤0.01% | 57 |
|
|
2016
Q1 | $412K | Hold |
5,000
| – | – | ﹤0.01% | 59 |
|
|
2015
Q4 | $524K | Hold |
5,000
| – | – | ﹤0.01% | 52 |
|
|
2015
Q3 | $527K | Hold |
5,000
| – | – | ﹤0.01% | 51 |
|
|
2015
Q2 | $684K | Hold |
5,000
| – | – | 0.01% | 50 |
|
|
2015
Q1 | $623K | Buy |
+5,000
| New | +$530K | 0.01% | 52 |
|
Other funds holding BMRN
VPC
Edgewood Management's BMRN Position: Q2 2026 in Review
Edgewood Management held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 10,000 shares worth $572K. The position accounts for 0.01% of the portfolio, ranked #73.
Edgewood Management first reported a position in BMRN in Q1 2015 and has held it in 33 quarters since. The position peaked at $1.55M in Q4 2022. 562 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.
- Edgewood Management held 10,000 shares of BioMarin Pharmaceuticals worth $572K as of Q2 2026.
- Edgewood Management left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
- BioMarin Pharmaceuticals made up 0.01% of Edgewood Management's portfolio in Q2 2026, its #73 holding.
- Edgewood Management first reported a position in BioMarin Pharmaceuticals in Q1 2015 and has held it in 33 quarters since.
- Edgewood Management's BioMarin Pharmaceuticals position peaked at $1.55M in Q4 2022.
- 562 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.
Based on Edgewood Management's 13F filing for Q2 2026, filed 13 Aug 2026.